Reysioie ridee@heurgkusc.co kr Sector Report Alt /Bfo| 2 7|AA|AA4: NASH NASH(Non-alcoholic steatohepatitis, IBY AIYAE 2 AOI Als SD} MY YS 2 VAS SS] SYS YEE NAFLD! aI YY MeO, Mz ArioIn| THY MBA, B71 ge Ia! IBS Q oy z Bele! WA BH 7IBL2 BY e179) 20-30% NAFLD, ©] & 1020367 NASHE AIoHHS 222 ujSHElCy, ¥IRI, et MPH| NASH ASSOZ 99! WS AANPt ei YeOw 20301 300% Sein| Aly AOA VV ALE richelo wket AOI SoHAA SUSE BROMO NEIL SIC. NASHALRNIZE BEI 1S Ol S FA QU YHA slolol Betowy vloinlal QA71 aoc Oleh SoH AVM AISR/HHO]S ALANA NASHO] Bela} BOIS of2s 57] Sieh HWSID Qi ALRAHES cielo] ADAP etc ie Heungkuk #354AITO, a > Heungkuk ea 718 N24: NASH Contents 5 |. Executive Summary Ih Key Charts MW, APSE 1. NASH AV BS! A88t INAFLO8 NASH? NASH ALR ARS. 2, NAFLD} NASH wetiejer - NASH 82h EEE ol HA 221, 894 221, A 29! 3, NASH Pipetnes = _NASHY molsajciet =g7/Al ~ NASH Alstall iW FDA 7I9I=2I2) 2 NBM BR = 5p 9, e1OleH C2940): HH8I71 BeIRIO| BelRIC, 362 2, O}OLAK| (170300): NASH MoIsTA}e! ers1 Heungkuk a |. Executive Summary . NALD(Nonalcohol ic Fatty Liver Disease, wi@haia) AME aelet, este wheel] his 7 gu, EHSY das HAE AAG SHS Mole ABs ae apPheGR oe] Vg a Be, wlataad AWD, sleds) A] PzHANASH, Nonalcoholic steatohepatitis), 7 Als, 7 AMER EBB: Agel}. ashe] Yelea| ose HAV AoA ayo] 5 ol4b 34} So] 71491 AZ U EelzelAle| (triglycerides) $e WSS Heeb We WF Ge A) BS, OU AEA TS BY, NAA Yah, NAG} Soe Dae, SRM ot HELA NSH Aa] HES Saat AS vs ofeeh. olf NASH aah) a £4487] Bate), W944 Wyse US PF Q ever Va Fee da as 7 BS Gola] Aaol AMS BH} OM ARAe|7] Bol. acy} NILE 7h Bohs oF SAL FSAO|7] OH NASHE Aaa SA] LPS el] ogc. olo| BY ALP, CT, Bal 4 dolar] § Hales A vel ot yt Deel ayy gle WANGIS 3SSeR Seve Aude ge Heee, Few se} ge lee Hate & Aa Be Ae] AES S icfelat Neh. 20208 SLE HallsleHH (off-label) F412 2.400% FRO} ABS YAS glen}, Alf SAL} eo NAH Alea) ALD} OVS Wd ee AasD lh. Aa MS UAE 7 Wo] ASSIS CHES ve, wee yee} NAFLDS) WE Aa} eo] NASA eG AS che}, Misia] Bele Valsad weal] esky, FAA, BBA Ael, Mole] AY 44 Plea Ay, Abs} asa, abs} ARalAs} vEeEelst eae F le Wale] BMAow Bese MUR Wess Ree eel gy SMS dese] ee shee He SAE Beteleh MSHA 24 sol GFE Velo] Asi] HE, FR AeMe) PE aa Seley, 53] 14 449] dy) az, late as ws aut az, @ desl aes vlale as SAAS AY Sole. PR AHA, ACC Asal, GLP 4-8 Aa, PGPI/21 HA}, OcRe/CCRS Fal HHePeL 7/419] CHES] 7PWS|st gle, acto} ofa] epgo) aesHs Dual SE Triple @¥io] Eelsz *el alate. FDA: NASH AlEAl NES Selsp7] Saf 201d NASH AKA PL Ab 7ho|Sebels Wah. ole Waaon Baa Lou}, oS HI POMONA] ASH NAS ATs AE BE Ae Soria te Fy NASH Als ge 71YLS ALES EAS} Buy, SHA 360,000 Ave) 7A] S|, AM OM USWA ugha aloes use Sobol AE}S Aolasheh™@® Heungkuk mev/siels 3364 71d nie: NASH ll. Key charts ely AC! Zoln| NAFLO/NASH 2 aH NASH/NAFLD Spectrum Nomallner tense) wroteon stress flroemvemnoss “camera” O00 7-w BOY, son om asm sam 3am 2m | 1am 70-200 tmocesson aca ‘wmaorenmaa ‘a ce Bay ie Snes avr, BASH AHA vaya NASH Alaa AIRE eB ete 5,000 NASH ALS AIS AS 2.886, 4,000 3,000 2,000 1,900 ° ee ee ee TE hakate Prova, FRED SAUL 2u3 R91 Agziel Al Wer ae cr] oe uielae ae Becta ngrg Sat Tell BE leet ABs ue ao ot 28 ol 28 ol apari® ele Av 72 aval a 28 oS BIS Avo ABS o1Sz=e wo ot Buse aa 2 07 ae ot aBteoict BB eAwote ele ape EBteolet BABENe, dae Sa asad 2B, 7a 20 BS 2 eit ay ot aca 288 eaas vise, awe WE Sania Veal Coronel 918, TAG AW, SSSA TAT1. ger sto12. Bq Heunakak eeAITO, 2124: NASH T.NASH AIS G3 YAY NAFLDS} NASH #1? NAFLXNonalcoholic Fatty Liver Discase, We) ANB! alaolet, Bats Heefo) ge 7H, ALAA Wb HARI BABA FAS Mole AMOS Pe AH ols] 2) ‘OE HE, MLS APD, lela APHIS, Nonalcoholic steatohepatitis), AS, WaWSs Rests added. Mss] Wel Sxose Dae aoa ap 9] ok Olt aslo} 7A14e Ale Ul Belted Ae|= (triglycerides) S2 AVSS Heh 2s AF ee AMS, ESAS BE lel, NE Sash, AG} Gow al adh. abel GALS] NLD SAEe: HE APSO Weis], NAHE Wals|ane Oech. ee 2) WANES WAKA aoe) Ae) Feber False wale ie aeSe] eve MAE] A]ze}] SS IF NALDS} 4IZHE eel NasH= ZANS]T}, NASH 2b] ef 208g Abs] lod ehh Zravios: Aas + ge}. wee Aedes Sete) oF 12 ee} A AESHHO)S ABTS gles waved. NALDe| He Fe] Maps] TSH, Ce Aho] ok oar SxIsfo} 7pala|el ALE YF Eel ‘Hee (triglycerides) Fe AVSS HIT, Aes] Et He] ae ww ot ey & UA Boe Bole}, we atsre zsleo] olde] 44 BHF 2g, vale} B+ she 30g *IRtolojor se), ayvHeel Zhalah, wlolelAg wel, ey S che Wales whalsley abate. SEM LF FES MSI AMS) AMES Sass Ae MS fei. ols MoT Aaah 7] S194 4A] Mate, aes Woe eat WS CEST Wg Faz elo eee ANS eal] aado] Alas 247) whe aleeiol7] sze]ch. alley} NARLDS 71 al Babs OPE Stolz] AES NASHS: Aeks|at gles] eb el] fee. lof AHF AGS, CT, ARS Yelialel Weish= Walepa vio] eel] S ulalgea alt wel aie 7h ete) Aes eH, nas NAFLD 29) 2s 2& me aa css! Smpk soatoss Cass 2 ‘Stealoss and lobular itanmation Css 3 ‘Steatosis and ballooning degeneration Css Sleatosis and balloring degeneration and ether Maly hyaine body a boss AMO, FRET AMIRI 6Heungkuk IQ} /4}012. 1. daca 2154: NASH 2a? eet OHM NAFLO/NASH BISH as NASH/NAFLD Spectrum net Nasi Nast Nase opatccetaar NormalLver —Glesoss) vofross —fixoslsfrossrchrhoss carcinoma O00 -" teomeiGth spay om asm oom aaa zm | 1M 70-2004 ‘ocatsson 9 cant vwivour cess AB nea Sec aves, BER STRATLET Ses NAFLD 8 Gal irhosis AB Fretior iy Parasleey, B38 OWE]AITO, > Heungkuk 71 NIA: NASE 3368 NASH AIRAL APE 2 HR GA MSHS ASSOB SWE Ale yHo8, Hee 4} aUgel olzE Ba} TRE Ache BFLAle) AES S 7] Be}. 2a 7]EOE Halle 2H off-label) SMOR 2.40028 FV] ADS BAleha gov], lo BA, gow NA aTzA AAR 7h OHS YQ OZ as|D seh. WAL MSI clazz 7PF Wo) ASST HES MEE, SLoteleleole}. POA MASiel AGS TER SEES OAeEES Asia ge. BEB Pegs} ease She ASI RLSo}A AW yEebO}, MAINE Gael Pest Walale] BY rhssha. nko] 2%, sbi eeu Abe rHssiehat elses we Sa] MSI] 7H FS AMS ASAI}. lovely AS Pe] AWS ade 908, Ase] BAS asec setae Meh Aalst Ach, Ket apaete] gis Abel, Al MEDS Bol Tose] Ae NASW wet + seks BS Fekeea whe ales] a4) & ASTILS V+ 3d. uo NASH ALBA APE 2 Rh coats 5,000 NASH ALS Ala AS 4.885 pole «onze «=~«taE:*SC*«éME:*C*«iCS*«é ‘a auate Pree, BRE SAATB® Heungkuk series aaea 71d nie: NASH a0 ABBR NASH 24 BS 90%) 80%. 50% 70% 0% 50% 40%, 30% 20% oe 15%, oe 10%. ox + 10% out PPAR” VisminE FR Slhmarn ABUB — agonist, agonist agonist ‘eas ISS ER, BSSN ARI ag ABMS UZ eet A AS 35% 20% 25% 20% 15% 10% 5%. ox 4 10%. ot PPAR VlamnE —FAR—‘Symarm MBue — agonst_ gon agonist I oan 4 R91 Aga Ala Wer ae a cc seeie ae ae clatigais Sat ee pcs ay oie a set sigaelele glee Med ig alee ale BB OSL ANS 7RS Aiea ASRS nleze9) Be ole aa BSE ay ot 201s we oe -Palasalt PE AAlvoIe! Acta saalasotch -Balasale ‘Palgolc, Ziel 3a asaael 88, 284) aks aa let wy ot smteiBele v3 ae eas iso, aztlet IB Sumiza Veal | Castroenorl 018, GAGA PAS, EFST AML1. Heungkuk _ Mey Hels 338m 218 nel: NASH 9 MIERIE + OBRIES Et SEAINASH with T2DM, n=105) Te BIERIE 7h NIEIEN2SelEHS enc conn MO) vow sexo genoa aco ewan OO x soxiorees ‘ast 10 v0 to Ayaincoon) anal awsio0i8 eeinn018) ‘BAluteslpH0.022) vue sue ‘oun ne ord soy te 20 eau ta ‘Baca ates Coe OW, BAST ATA 234 MEV ASN THE NASH 7AM AS Sa WE wae a eon teri ne ma 96 2660-00 sASsegereet eT} 90-0001 CCnarinNASSm bine —-1S8037 9994013 4942036 3442029 410202 2001 Sete mone W249 7G m6) GH — 2940) Heungkuk er/HLoLe aaea 71d nie: NASH eUSeE Phil uvlal ASS Falls} Veg aAlalee ele MASH oleh. aPE 34 AWS FHAES BSA BS Abe) Eze, IL-6) Abe Salslzi, oF a] ASILES MAES), MAE, BSP -S GO Aa WARS Beh Cul MSS ASAI, ER TAAL, AY SAM Bde ole] Ao) ERSe WCE Bah) AD, HCH SA, BES S71. ACh Ae GALA Fe Tha, IL-6 S Ao] SAMS UAE UH AS 443} lea AAS feeaeh, ole 29] ARS, AS, ASol chal SHAS} ae WAAR Fa AEA, AR Palo] lai Geos eel HC BLT AT, AE Seas Shalala Ast 2 FS pelo) sels] Aes GI. Fz R/O Maa, 1008 BPS lala, ahete-3 lala) S2] eee] e424 vealed] alas}at gic}. Che BARS HSCe] NASH Bel ALSolAle| Hetoleh. LR Fah ACHE, DAP, AZS| AE BS} THAR AR HABA WSS AolEAKI, ABIRISS Ball HSC Sga}-lle}, ols yale! WSC Bebb ches ths wel, AN Fel de] dy BASS Gee, ole Ses Hat AES) 712 Guile) ahs ebalsiziy, Wsce] Myss Talal WESS ose] ABST Me. Fel eS Sess BAe) LOL”) AlaaVh wes NASH @AHSo} le] LOZ as] Heol chet ehate] alae]at ge. 1a) NAS (NAFLD activity score definition Ten Definition _, ‘Slesioss Low to medium power evalition of parenchymaliwoverren steatosis Grade SE Tobilernilammaiion Overall assessment of alliniammatory foot ll Wotecl o “ie ber B00 xed 7 ~eatecpa aborted ———SOC~“‘~—;:S*«~ a 0 i 34 Tes par B00 xo Ballooning None Fon baloon cals alefporineni balbaring 2 nas: NatNAS ee Bordering 8 NSE m8 {HB Molecubr The apy Nuk Ais 2015) 6 252, BREA ARNEL aig Heungkuk (feels 3368 2124: NASH 3. NASH Pipelines NASH Bto|Hetohs 2187/4 MaSHAleAlS lel S>go4) cee Belo] zee] Gol], PRS alee] At aed So) . $8) Ja So] ob ae, aalel SS ws Het BB, 7 tsb aS Pale Dae: SUNOS AY Sele. FRR 2}GA: FIRFarnesoid X receptor) 2: ts} 24o| Seal Washes +8aolch, Bee FuRSo9] 4iel eles alls} Gysre Qe aeishat, elevel Wade Saleio}, dal oe US) AAS 2a}. ARAOS SIEVE Bore} Ae] OCAobet cholic acid)7t SUC. OCA Zolotd ella STAstolAl Zt AAS 7A oles VEsES}>] FDAS} wel 4) HUAS ABM, MAS VF FAAS AFI] Sele Asa, al a EVE ROGENERATE $7] abs alagshSt gE}. AC Alaa: AOCCacetylCof carboxylase) 212) 4'21 Uh 2212] AA] BA acetyl-Carsh SHINS malonyl-Cors Sula] ALE Ay AIS HSH, AE AHS ehalall ApS & Haeeh. Selaks 2020kdel MSH FRE Accalsal SelAbseAebe (Pel6221304)s eet CAO PERE, >t FY 26 DGATZ Aaalel lyr Lee Pr-OHRSTTL) 2 Qo} WAFS] Mic NS AGSOZ VOR MM MACEM OL zg eal aad 28 Sel, 20244 gee! alyo]eh PPAR 4}: PPAR(peroxisone proliferator-activated receptor) GE a} 3g: 2a ahs es Bash elabel 48h HEalelch. PPG Ze RA HAAS) Wel SUSU], PPRaS] BIS Ad PES VFM, AMAL MISH, 2d HS, RoR eS ees Haze) WS fetch, Pry GA sea) Wsiead, aed asiel at ott Zu HES AIS ely lee Was dole. Ae) HAS wa Salo] els ASHE Fisch wht Fae Vee] seh. ARGNIT)S| Bef] Bebe 27} USEC PPR Atel, AAHREMLIE IDA] 2s} Fle ws ols USP A Kain Ve Suse. GLP-1 484) AHA: GLPL(glucagor like peptide 1} 24] 434) 4] chee! BHIDS Sale} 2, PE HS ahs Ho] Helse SBS. GPE He) HH EUS a wel] H8He|7] HEH DPPtol| S}a HaHE|2] GH GLP-1 4-84] AMS eleiow He) Ale Ae. GPL Pa) BAG BS Be, AS a4 F UMS HSS Bolted, 58] Nsiel shal he] ayy 42s} es we ASKS welts Ree dealt,ig Heungkuk 3368 AITO, 2124: NASH LONL2 atl: LOX(Lysyl Oxidase) Al@2] Ht Hel Alt SRS Salehe] 7 AAS Be, Bl Hales alec. DelolsAbola Ae LL HACE Aalshe Yale % Simtuameb (4H ABOU, IE eo Al) we YHOU YESS Wy sate PGPLO/2L APA: POLO eee Ab ASS Ste, ANAL Md SS Fpal4y7] 2B, 1 Pea Hy R RES aS cali, ee dae} Sed wll she] Bs FFI9+=A)7} al Habgch> APaeyt seh. PaZL A) EES} alalcAbl Helsh> a) ghee aD de wl ele WS Yo} sp] zieleled. He WESHL als Sol7] shal sof ASS uu THEE Atel det See Moly alas Ah, Ocea/OcRS atl: COR(CC-ctmokine receptor) 2] ABaks VHF vlawewals a YS aoe Beis DAA) Wake Feel ze] {Maks feted. Nass} viet ARS coRaY} CcRS7} APE ATO WH-7t Beh. Welz} Cenicriviroce] NASHS] AES AWE dss Mie, Ws wey IS das ade] Sess. ASKL Aisha: ALE hol} ISH PISS shel AIK AP, aS, ANSE Salah ch A Mae, AGASS AMIS Sabet BS, Sel AY, ES] 78 alas Geel F Aas] Skee Ze TG Ba ab) alee}. Delle 7h ietebel ARAL 4) MASH ASSS] aS AlefoR Selwe Roe 7hmou was HAA WPS Sab] Rein) Ie] Oana.AIS/BtO|S "@ Heungkuk 71k Nel4: NASE 3368 2517 QF 2/324 BA BA NASH Pipeline 87140 Be ‘I Naure Raves [Casvoariaraby & Hestgy, S352 ANTE, vas NASH Maal 27181 cae wa ual Hepnaby 278 vel 8, SSH ANANE= @® Heungkuk aex/tiols. e368 71 2124: NASH 28.13 Pharmacological agents under developmen or eaten of NAFLDINASH (1) ‘Highest developmental stage/ ase Tents tn cons Ee nde van soon rian rcstPramamiiat —yergey pus ineen Pha Grid mete rian srerxPhamsece 28 crn TwofocrUNS) rer BAPRar — stom ann vrs ee — vo NARS coma we sa Ran craraPramndiie Ph 2aNETBNE EH oser Piao Gla coe Pos NTRS wen PITS a a od sr rte Shofiomscecee —__PassaNSTETETN Flafbranor PPARa/d activator Gent Phase 3/NCTO2704403 oreo sens real 2yrDeraey Ps nero visi Pon ate ira tame Pr heres oto bate en Pr here coeare sec evi Gi eres Pham cons esr Acoenbrw Pie Pr 2a NTozne ee fan S00 Gates Paracas an ozce Pct shone reo 9A te Note ram aeroierere esr Set Pir Pi eos — en Vises Pam aNCTOT eon Te tr ri Vina remnden ha aT 1a SLT be Nos Pr ANTONE 0 rer “ a Erte Phe = cons ti Contant via NTRS Scr 196 Gi Sere Ps TORN SSC nfoTnedoro char Pg Pre NCTE nie Annan al (azD4076) _microRNA~ 103/107 Requirfaskazenenion (giscontinued)/NCT02612662 "AB: frontersisEndochokgy2018), BEM BARINELIQ} /4}012. a Heungkuk 714 N14: NASH 53120 Phamacolbgical agonts undor dovlopmant for toament of NAFLD/NASH (2) ‘Highest developmental stage/ Ones Tastt ion compary reper —————E——— va supe Plo oe ancrioe Cees atone Ain Pr aNoxoe70 avers ae socom Sesh oetomPhamats Pas ZaNCTONETSS coat Helier oti Gale Ph acronis Tipelukast (MN *t i ie LTPEL-40 rnb Wadena ase 2aNCTERES5 Nair FS “Ranacost Twat Pamaconca Pas 2NCTOMGERT cree ‘sat at a-fteBoptoma Phase ANCTorora14 Dee r=) eee D8 Bopwmaltmrne Phase aNETOZOASA oNO-2 Car be Gath Tesoetes tae ONCT2ACIET Pra 2 Smaniraies- Lowaentr GikedSserems (corinne, _ SST croer279 BS DINO = aa 7a te rkrous Preheat —— ete 2 inmaen Pra 2ancronter? setrenyen taco arte conga he Pr 2NToRO59 Fosos1 HI bir FotnarraRoe Pras N20 s0700 Laveen ‘si Bram Pras INTIS? vow Fors rao vow a0 Pras 2aNCTEPNSYE aus-286%8 Pras NCTA, (PEG-FGF21) FOF2T analog ews NCTO3¢B6912, Lilie Lr want Now Norse Prac 2nerorzri9 Sensis Lt eran Now Norse Pras NcrIeTIO? Pras CTOs Stagipin Dep s rnibeor sD ‘Not apolicale /NCTO1260246 esin ao tr os Nevalese heigl? apa sanaesee nl Serums Pras 2NCTIOTI9 ucaonie-t ecpe oe el Med Preelncalenaie ussoonCPIL ep il Phas Ch laa vansen am a Paracas aa aes, Neuse corer vow a0 Preelncalenaie wasree cara i anonst Yates Csraon Prelacalenaie "RB: FrontersnEndochokgy 2018), BEM GAANELa. Heungkuk 3382 38121 Pharmacobaical agents under development for veetment of NAFLDINASH (3) ngs Target of Aton Company Tropiexor {JNAS2) AISE/ HOLS Jie nie124: NASH oonenos (ove) PR A9enst + CCRZIS cual antagoist, Novas + Aegan Phase 26/NCTORSI7S40 Selorsaris (G5 deormeg ggve+ ASKCT nhbtersACC inbter+ PAR Goad Scunces Phase 2INCTORTEISHA, 5-9674 eacrist NeTaseaa446 "RB: frontersnEndochongy2018), BBM @ANNEL 282 BOI NASH ALBA R718 RE Poe, F358 SAAT 20ig Heungkuk (feels 3368 2124: NASH NASH A12AI 7% FDA 2ro|E24e1 ASHE NAFLD] SMES MAbs) alalsl= Seb Sle Sako] Salslz) 7] aheel, 27 At R Rt felch. Weaglel ea] A zy Jajah Aaaiel AS wSoll shal Be Ae] Qelel Sa Wee = NASH Aza MARES Biol eat cabele Aalsheel oe Al Sey, elo FONE 201B%! NASH ARAL 7NE QE lol seals WHET. lt Cade. QAR AAS WOU, ols cls eo} VWatsh= MAS Alea I MhYS shehah Bata eich, FDA NASH2)RA 14} Awol glo} eletel StelAHKGeneral Consideration), 271 242 4, £7] WA, Wastes] Mew 71S, eb del, ws AVP, eee ate} 29S tat NASHs] SHI Aehe OYA HES] LAVeIe] Aho} ele reset] ole AGA A AS WAG AS AHS AF Ase slo] Paes Hl ae4 sel eos 188} AAS AAD +H UES MbolomlS AMAL ale eleetat slo}. Se) zeae] w E S49 Melgevls BSE AST aspartate aminotransferase)9} ALT(alanine aminotransferase), 7 AME B24 AEs Ye Vt GAs Poca} aes B4e AS UM. Le 27) dolls Mais] ABA} Baolal= eat, Bap w WAYS, AOU, ASS USE + Me Vd, Bale att SS BH + leh. 7) Wasa BS BAU AS A Ae Bale Bee] S7HE IS RIES al) AE AE AR Ich. MIR We] Saeaow Avis] eps BS deta VF ABA Ae 12-1871] }°F ah, 8, VSS MAb SH] BS, MASH AHSAN ALTY AST 4s ZA] A eleie] ol} Sv 24 et Uae ate se + one, hg eee wale, MebE 4 SS EES Mss] AWSHS BEE OES, ole] aMPe BASS 67h ©] FSS Soaleh gepst glatehat sly. 4 CALE double blind, $19F US eboz Aaeho} sie, WS PLL] AP. NAS GN ARS AF sol 7} AHS Halt AM] Vat, Aaleow ayes] 240] all ASIEA) OPE B7telok Beh. AI] AIL aye Belo] gov, MS A+ O- 19) BS 84, URE Sasls] oWoe Bole eAR-SO] HANS NISL ORY ALES} ES eee o}4) MRs|7ie, ABS] esKNIS a 2 Baa, BS, WS ate] Sv} Mart tigee ae. 21@ Heungkuk mev/siels aaea "225. Endpoints in clinical trials on NAFLD and NASH onsen | td iron, —— hee ete EE OURWAL OF HEPATOLOGY,Ag Heungkuk 3368 HAIet/ toe Jie nie124: NASH 23AIS /BtO| 2 1@ Heungkuk 3368 2124: NASH NV. 24 SS 1, GUIS (128940): feH7] SaNeto] Bzigich. 2, SOOHAE] (170900): NASH MFolse}e! Bo3368 Aist/wHole OMe 79250-2836 rhlee@heunghuksec.coke > Heungkuk BUY aa aaiF 7106/14) 38cm apie ase S204 aa pea eames 203218 cord oso (4) Buea (12) 383 (220) aa) ow aE a5 AaRRIBORI a5 a a ag 76 eon ® rar 10 KARE 2 BS on one ae PR as a Se ESI 63 Hess ot OE i Ww RH i 292,0008 23.2% Ss a0 70308 238.008 oun 18 a8 100% ak vo Toe 85 8D isa 552 8 8,8, Wel awe aE an 12681300 "3 ie eats a7 @ 7 Su 5726 S08 55 alt ur a me 12484 we mow 02 02 02 at 83 S18 Sui ar 6774 Gr nose, 2 KOSPSHRI. AITO, 71d nie: NASH (128940) OFS gro] OFS oh] Bao] Sagi SAE sloletagol lal A212! Buy, SEF} 360,000R22 HsielA| € PAIBICL Holes Valiaionol: Gxt QI) Sel DUAL agonist (HM12525A), TRIPLE agonist (HM1S211), Belarafenib(HM95573) 2+4i9} 127181 FWD O14} EBITDA 2,128%48I0H Targel EWEBITOA 164 SE! SA71S wes OHHH] FDA Sel 4 BS SAE SWU7] BEEIA, EAISEIY 274 wlo|=2helol cha} FDA Sel of 37} GUe AOI, BEELA(Rolonis\e a8} UaleYos est Se PYLE HEMZ 2012 oS AMERIAo AlolMAOKE sigich Aa ERAS 20224 3B BLAS MMBslo| Bol oWl9e) Mole BME ate! DhstIch EX|SEMLE HERZ Exon20 Wo] W|-eALEH| ef Xt CHa At ‘SAMS WASH, SA] AMERAIol 2015 2Bol BlolMActRS| sich. 2EE29| HER2 NSCLC 2ka|aM2 THE Qaed Was ez FOAO NOAS AI, Sal 118 2 Mole BE Atelzpssich FA RED Holme}! oe ‘SALE NASH, NRASHO| THe S chest Ho|Zelels SrskR Ach S| Dual agonisti= GLP-12} GCG 0|S4t8M2] NASHA|ZAIZ 202014 88 MSDol 22a 7H/ Bol Werks elolirotse wc. 20210 7M Se fH Yaewel] Soiztt, Bet Y SEA ooloi, 2 Mol Br WE 7) HEICH Thole agonisti= NASHS HSS°Z ste GLP-1/GCG/GIP AS ASMZ, Za YOe SRY Bars SAA sew} TIME SME pan-RAF Mala] BvIEMES 2016 MESO] & Moka 9941 AB} Siejol Bol of-BAHCL 202114 SH ASCOOIA MH BANAL S 2} BE BEAEG, NRAS Hol SHB aA} 1398S GNOZ ORR 8.5%, mPFS 73H] BI} SBS} MLSS NRAS Ho] SAS BAIN Se BAe aS OOl|S WIESE YPD-1/PD-LIAE 2 BE NAAS Hol SHA RAS MIE COS Bele cle, ES SUM W/EIMESNO| IBY INAS wasn Uh 25x Heungkuk 8358 1, OHH] FDA Sel Ot 2 Rolontis & Poziotinib: ‘SAKE ae) SHEA, MAloe}y 27 Bolstedelol) Hal MO Sel ot Aaa alae] oh. BEEARolontise Ht YeAwos ele SFT: — RAL, Bal Ceol web a COPPA Fl 2A Adelle}, BET WASS BE aeeelawos ela WHs|is ALOE MAF) SO-TOTAS ATS ae WHE ose Bold aya ele}, AMERFE aor a SEE ast TASK ADVANGE, ROOERDSS BLAS ASMOub, 0rd 8 ALAA ofS CaL(Complete Response Letter, ASBAT Aye Bow], 207d 3 GA) MAS aS} Sa] Olea aol: DHS Atel 7ysHeh, i BEUA Woe AWNES SHI AOR BETAS] Wwe a7] Hye Beh 4059 & ILE eflapegrastin(s-196), pest ilgrastim(n-210)2] 49] Fo} abhor’, 13h UAE BPS 14719) DNCDuration of Severe Neutropenia, SESEAILS we] WOE, FS EPPTLTE NOCMdsolute Neutrophil Count, Ae] LE +H)7} 0.510, dolls lox. aelulgich Oncologys4] YSEEL ES] WE, Si W]e. Mo] eflapegrastin Fe] Bx} at F 15.886-31)L24, pesfilgrastin FFE F 2A.IMnSD Sh. Adel yew 8.5nge. , pegfilerastim THY) eflapegrast ime] 31.9% JUI4.os BRS Be] Ayah SEEAE Pula dst REOMERONA Be ASHE Waa}. et cabal ADVANCES} 7 9] EUs AAS, ofA) Lap B7}AgEe sols LAS] ONew TAS We 3 7) NSE Bh WIS GALLE eso] AMARA. ole] FU SERS ALS VA ‘HE eflapegrast m2) BF 20.98(-24)R27%, pegfilgrastine®] 24 23,2028) Be. BA\CE YS HERZ Exon20 le) a] Aealet G2} dt HAV S sien, a) 2 AEA] 20154 229) eolalao}s sleic}, wlAastatet ap ole] AEE gfe] Zag sigleu}, 2829) 2am debe qed WS Soh Poll OAS ASS, LG 249 Aes Ass Hel7Feste}. wlza| Ee Ba} S HERZ le] Sb vse] aA AAS Bao 8), Gal PAA)aAS H7WE He] Yo] Rzleeys] Sel oF AAR. HIE BEOLe 1@ Heungkuk 3383 718 NIPIE4: NASH ei24 ADVANCE 2% SIR} AIBEDOF vo.002/eamn3227, BBA ePIC 2425 ADVANCE Qt 22h B26 RECOVER BY at Too sane en aaeo 10 a » . . ee Sine Eo Eo t or 2 ge gz 40 eh Ne tba Faye Say ° * “Severe Neutropenia NosN fo 20 So Se (Days) Duration of Severe Neutropenia (4) a ov ONO SN OE FDOT Taos NES 2ig Heungkuk 3368 AITO, 2124: NASH 2, $2 R&D o|matel gle NASH B{0|2242I: Dual agonist, Triple agonist Dual agonist( 29: Ashe] ) Es GLPHIS} GOs ol-B-ale] NASAL 202048 82 MD) ee Ae eel ARS aolaAhs Beh. olseMiaHeb|se ea Hy) ASAE BS GLP HBAs} eA) ES S7PI7h SPREE EAL Ssh NiSHalzalelc}, 2rd 72 SEW gaze] Solgtst, Se] Sal gelmy, a dey Als YAU} 7d}, lsh YAS towscr|Aste| GLP Aha el Se 3 Alzada) Eso} wate 10S 1A} Y7A|E MIP SB SAAS ANOS 18a SUR AME ee Ge Sole}. alae ols | Aes go} Tale ‘Belol Upsront alee s eho) aes ofA. BARS Dual agonitol elo] Triple agonist VS APIS Aashst gh. SS eA) NASHE GLP-1/C05/GIP AKEA-EATCTE. 15S FDA 20208 Triple Agonist $ NISH ALLE BABES Het jepyou aggzonl, get eked wetel(2od) Fas gah) wie (2000'd), Subs a AFH 202112) ARS HS arses aged. aa Sew dy 2h daatst slomi, wd Vt SR Ae}, Sal kee Sash WAV 7g. Belvarafenib SAKE par kif Hall WHYS 2016's alelstol] $ ales ge} 1alyt Beto] eho}ala. of FAC. Dor 5 ASMA] SU) bib? Sal ASHE YAEL a, RARE fab} See ole 7H mS Dt BSS OOS Pt ayy AES] eae aad HL, RAS Bo] SHS Bap YS GS ORK 38.58, PRS 7.374212] Asp} SS sige} dvd 98 ESE eebY yy sl Ib eel Aap} wsEsHelEe), NAS Ba} 195 % 580] PR6. 9) VSMat, aPHST 7.37HAE Hebe. AMES NUS Ho] 4S Sho Sel AI By soles ves WYP AGS WE NUS Yo] AY SAS dels valow wel gelaa| Be stele ay aS] NBR QE HNCTONGISGOG)S Z18F}SL CH. 28AIS /BtO| 2 1@ Heungkuk 2U& NIel&4: NAS 3368 127 NASH Triple agonist 728718 The entire cond EERE tne + Acct 0 ie er Oey oF aes — oboe cme YY Pron serie TRB sot ssa athe — e \ \ 4 ZS, Aa GOS, BASS BAT 05128 2021 ASCO 37H Belvarafenib Qh bY Hs. Gloles nec Reepone Rate ne) 21198) 5085) excl 120 2084 105,842 npc Respone Rate (Contes) 1) 2005 4008) esx rans 00.0145 Diese conto ate nc) 3038) or) sxc 1250.20 ai, 9814 Progression Suvi Medon 73 int sxc 125NA Duration of Response Maden (ont sexo S05.NA Fa BOE ASD, ES AE 2g 29 NASH ALBA AGES B30 SE SLIM HO] HS mui aaa A Be se anes Vf anatore BUaD BODIE Bona 2020 2026 2005 20288 ts AS: abate Porm, FE SAS i Recorchion, FRENTE 292857 BOIS RED Aer my Heungkuk 3368 ine AITO, 71d nie: NASH Obesity! Nasu Diabetes Oncology Fare Diseases other Biolzajel a Hurst35-olal BaUeio|= HurzaTovotn|B2ieiol= Hwi2470 one = Hyisatt otal 281-0 Her6s2 a9462 HW16390 Hs120 ogee geet 2950 geile wise xan hwisatt 5450 Hw1542t e329 ALG-toot Hv15136 Hwis012 olnlzojnzut ALG-toot sels ro age Gheagen Combo wlRhtAAye BE Insuin Como we ulin Arab we ciricos ina xu Tole Agonist AIBA} xd Araba ae EzH/oMsin| Deh BE sost Beet L2Araba ae POHL leet 88 we i 2ee BTUs Fotos (guFoie) Par-FAF All SHE S BO PO-I/HER Bao Bee way | BUFHO Bt Pan RAF natal a ParHER — NSOLC1 AI XBRL cons Beet “ble Agerst SUA AIS Longrecing ASF RCIEhA SS Loneracing GA shalt wi auaed Mae Luinate wOmesaAS Glucagon frag MMS Teles GiP-2inabg ALE rH wyeee 2a Foldols ies eters Bik pte aweht aut ae ate aes 2 28 a 98 ae wel nel need aie aie ayaa aa 2t wel we ae aya ata ewe a oa ee eae ena Genentech Innovent emso RAPT aptdse PaAllegro PaAllegro AMfaMed soos i BE, BREA ATI 30™@® Heungkuk mev/siels 3368 71d nie: NASH 3. H0|s ZA WS Fe Valuation WHE Geeks] lel Fabs Buy, SF7b 36,o00ge2 wets aaleey. Valuations Ga} Ql4t Sel DUAL agonist (MM125254), TRIPLE agonist (42115211), Belvarafenib(1N95573) 7141S} 127481 FYD of} EBITDA 2,128°] 29H] Target EV/EBITDA 1613 Age She Beate. ‘PTH S| 2008 A148. MSY 1 2.63194 AU yoy 45.08), Fee] 2} 1.22084 8 yoy -2.88) ©. = P00, 12 aa ae WE Melee) eae AC a SKN) TANS He Al eral, hese) Maoh] A ae] Peale. eral dS wer 265218 — 1022 327218 (yoy +22.9%), obezretH ee] MHL 1021 2872141 + 1022 3192142 Goy HL WS Ait Fea Ieelle] As, HAMS 2oorsst PAE ae Wie] AR oe) WSS] 7h wes fold Ase}, wel oes elt obage) 89) S77h eae, sex WOE BY ee aa [tos eaei S02) Gai) 1022 SORE GOORE AO] —_—n001_—SOORE_ OEE sat os 2s 793 903.1 3805 21.1 23 OBE 6.3] 1.2082 1.2681 1930.1 Yor) ith 7% 195% 254% 198K 99% 08K ian 11.8% 50K 5.9% as ee 1971 2006 2252 M10 BAS BG 2059 ee 9170 989 TaNRA Bai er 74 695 784 Sod SHB BATA? Toa) 2887 3IO 34 atoraulaiz ma__20 187 s|_a7_ 227199 meq 72 O55 waert Tau ta79 7027 1058 Vane ioeaiaee 1094 TOA sea.7 BO? weavers) s59% 494% ATI ATR] 46.2% ATOR 73K 472M) ATAR HOOK ATK Yori) 0% 219% 16% 4209] 186% 11% 19% 14x] 150% 99%_61% masa wed iid W604 1847 1727 ead —iei.4 182] 6828 74 THO ca SAN% 506% 520% S27R| SBR SBOE 52IN SRE} SOX BIN SzTE YoK's) =09% 90% 269% 151%| 191% 88% cum 1x] BOR SOx 40% ela Tied 1265 235 4291919281986 159] 079 ea —STES Yori =ai% 54% 22.2% 97s] 194% 100% _a0% sex] —4e% Btn 40% ‘Saioley 29° 189 36.942. 409 276 264 29.1) 1254 122.0 126.4 sseleiste) WA% 57% 122% 12.2% 127K GOR 80% BAx 104% 97% 95% ves) 42% 406% -242% 1.98] 364% 79.9% -CO.7K —wor] 156.1% Zen 2.6% RaSFEoR CT New) 70% 25% 77K 50% GIR 7.7% 38% 40x] 56% 55K SER Yor) 162.0% 49% -I75.9% -O7I% 25% ZIOK% S09 -B.1N| MOAR 428 40K RE HOS, BRST ran, 31a. Heungkuk 3382 AITO, Jie nie124: NASH os BOI #708 OBA $0] 400 280 300 280 ‘2018 "2000 B01 =20: son 208.7200.9 10 Ey 20 ‘ems GOS, BREN BART 2334 WOIE 27Iz Bee Fo] (siete 50 goo o aad 25.9287 go [258 20 10.4 2019 "2020 mz021 w2022 38.9 29, “22.3 10 20 40 41.9427 WR OOWE EEA jas BOles Oe OAH Ha cei) 41.400 1,200 2 yore) 1si7s a 1,203.2 1,118.6 4,075.0 1,016.0 41,000 800 600 400 200 2ore 201s 20168 2017-2018 2018 2020 2021 20226 20% 0% 40% 20% ow 20% ‘ems BOB, SEH SANE 32™@ Heungkuk mev/siels aaea 71d nie: NASH ase BOI eet Bele BE (asia) sme 221012] 2 0? marant 200 18% 16%. 2000 14% 12%, 1500 10%. 1000 ox om 509 4% 2% 00 ow Bora 2015 2016 2017 go1e 2019 azo” 2001 BoRZ ‘ems GOB, BRERA 5337 QOIeKE SOTP “SRotoltt ee Vale a2 (eel 7 3ao88 2128 12M FWD EVEBTDA 160 Target EViESITDA 4187" Guieeoia iaata DUAL HT 25050) e134 TAPLEIHNIS211) 1207 Bekaralerib M9573} vars Benda 950 Nv 43082 BSAA) 12078 FS 7B 36,737 SER) 360,000 sue HE) 292,000 Upset) 233% me eage ein 1 OS, BRE, SBE, AN 2022 EVERTON A 331. Heungkuk _ Mey Hels 338m 218 nel: NASH 2238 NASH DUAL Agonist (HM12525A) 11242! 744) 2002 —202SF 20R8F —20RSF DOR6F 0R7F 20eaF 2000F 2000F 20S1F 20GRF 2050F MSTA ny 18-61 14H? 2.954 46506. 10409 THR m3622 TROT Kas—1 SAR anisee 1.25% 250% 5.00% 800% 9.00% 9.50% 10.00% 10.00% ons SBCA 6 HB 594,404 402 3.550 4.858 6.915 B2He| 7 2 9 12 20055 ae NoPLaT 51 159 460 1103 1852 2781 S75 48a wace osx Wy 3g G8 307 689 1087 1503 192.3 2507 Neves) 799.4 Tominal Vali ete) 2,267.8 arurineie) 6134 ‘fs: Gakate arma, SEH ANS FREE 10H 7, G79 £5 72, A/S AB 11208 74, WING 225%, BR 2006 75 22139 NASH Triple Agonist (HMT5211) MOHEeH21 7/X) 2020F 2025 2008F _2009F _AOGOF_2OSIF CORR OSE anseF 20REF 209K Notetaagey 2 o5t 10.499 15.748 23,622 93,070 «2991 55,889 67.067 77.28 88.595, ARS 125% 300% 5.00% 7.00% 10.00% 12.00% 18.00% 16.00% 15.00% aaa 148-534 7.585 2616 4858 7.579 9.852 19.073 15,094 Batel 15 531332626758 WS. ,g07 1,508, NOPLAT 4 108 08 STB SBT THM 1.018 1.165, waco 65% Bi — 17 8 Gd 1107 1928 780.4 366.5 ABE? BBB Newasete 15286 Terminal Valie(Met8) 5,681.4 appin(aleie) 70.7 IS: fakate roma, S35 ANAS FREE 10H 7, 7 25 7, A/S A 1120 7, WRK 225%, CBRE TON HS 10 Belvarafenib(HM95573) sho|x12401 744] 20R2F 2025F _202F D0R5F 2006F PORT 2028F 2029F OGOF 2OSIF 2030 2035 sae xa Absstapisey 2760 3474 9.650 4.108 4.927 5551 984 7.302 11,165 12,801 ARERE 1.25% 3.00% 5.00% 7.00% 10.00% 10.00% 10.00% area e216 5668 1,097 1,262 1.051 eae er er NOPLAT 61 188 21 5B 850 978 1125 Wace 65% 43 112 201 02 a6 009 Nplate 2188 TeminalValite%el) 520.9 sea inlneie) ura HS Moretearerco, SEH ANT FORBES 10% 79, B79 555 7, 20 OB 11081 7, WEINER 225%, BR 20% 71. Heungkuk IQ} /4}012. aaa 718 NIPIE4: NASH yBopIIA (ste) teas) I 2a el AEE NE ‘alm aE ueet iors9 1208218.) 1801184 iat Ta) SBS 8G LT BIBI) as “na “sp "53 52 vo zit 15805 Zea aor ee Te snl 225 1955 ao D8 BIB tes) 9 11 ew a8 18 sos 02 BS oa ea IDA fins 23 a8 8 208 V2.7 1288 Rs 86 1088 siete es en Be) es ee ‘m2 ams! 284 m0 220 sonnel 4) (07) 38) toa) 68) ee suet 35 0D ft) os) mo m2 a6 97a AEB! or wiz saa ih) 5 me aye BE sas ‘seo a0 sma wu igor Wa 15 12TH ‘so tend sd Skt AORN = 079 TAT REKERSH au 52 79 ag m9 BIB IH) (oes SiR sis? S95 52 A aa SYOAGR Aaa asone ove om) ss sa gates ee a SOIR) «= (SMS 58 20s HES m2 m2 m2 GemDeerion) =—73 Rk) eas 432 mz m2 aa SOS) «SBS S140 (ORO Su seo sw oO ‘E1860 46 e975 ap XH (irs) (ore) ns) 53) FSIDWOS) 1378 tea tO gO ex (i) tt) ton) 2008 (8) vb ts 5a 505s RRL Gig eas 20 Tass toma NUT ws Os Te mB CTE 1.7 149 1482 att 13703 De 3 a) ma owls OM ese S45 8301580 (emmern (um) rs) 53 D218 a 3838 aD (cae os 9 m9 mi me ME 6 af es oe fed 255182) 2668 se 7032 FREE erage @aegE cern I 2a mel AE EE we acl owe EE Paton Daa wea sls aia tas toate Bs sms saa 57259 gone 638 IER wa 85 2a ws GUESS SATB OBIS TETTLO MOA KER 3 lms wa wes 0703903 wo OD SENET 2) (ss) Ba ea) Bie) ati) apeUNe 5) 27004) 07) re mm? 07 Sk 8S UMN) =a) 88) a) re SB 42 tka) G8 RAPES) a) fto8) a8 vzame 63 1 m0 7 ak 2 a 9s) stele oi 02022 ag SPR rn en Sb te Is ERB a 00) eb mR di 28292828 a, 8) (08) os) eat) waa) aaa) ssunaus (38) ia1)__t3a)_ tt) ton ‘rug 2s gaat (e233) (za3) (os) 12 Netdiay Te 87 512 mo BREET (ig) wee) 7s) ssa) 70 eseienOR «SMS 2899 OHLONE, 12) (08) ft) =) Eg 1is2 es wre 2 so RE ass ao 53s saa 2 17 a9 75 Te wage 00st _f68) 60) nas craig 2314 1) 1318“ SRRBRIGemGA) tae Za va87 168309 HS a ee 5) m2 mem) mas 4S 3 mg 2 RENN ie zs 3897 (38) 41) CGH) 8) ton ERE Fees oe m5 A eK 5S stats) ®) 49 63 9 ws GEN ) 09 gata apres) 517s? Bt my me ots e183 Baal 35Heungkuk 3368 ig mero, ota ozjaso.2096 rilee@heunghuksec.co ke Sr sds M7106 /14) 62,2008 aac 30.2% avis, susie ware aun 52 804) aa sano) exon tu uaa a8 21308 2028 3255 (1 90% Fae (112) aK Boar} (12) 5% a ee eae 23 oF a7 sapeguosy as ey ot 8 (or a 8,4) mn mn aE oo 62 se 8 Ss 8 ® 2 2 & 17 sa 49 029 ws a2 0 m2 0 ie 18 13a a a) BNSES 95 T2988 FOL seman 2 SS eeoettie m2 meet ou ® 08 2 AITO, 71d nie: NASH (170900) SOpo|AE| NASH To|Zefel Bot & see Boats ese Ps 2 fot Srl 17262 ADAM elgiAs EZ wesHD. ofS] 471 Bela elalolal 1 HoiaPebIe ce 940i Bale Gm, WE AAA nen sls] Solace EE BBO! Clal Sele ofBIolct, SAE galt] AH o1F, tooo{7H Bol wlal apt elat a! go 2ix| HBO YASUI, ool chal OE MIIgkD VeAIAl 7hatsOl wt OHEO{H Sel ciGInIal= ob} ols} Bet OlfO1A HolgkcH= BEIolcE DA-1726 HIBS SAAat Se O13 SLWASIADA 202201 ELL 21M] LBA DA-1726'9) 2 a) ott QBS WHRICL NASHE HEH] Fist OFAN! ‘NASH Act 2 MBet F, DA-17263) MICSEbIES 224 Bol Zia aloict a LZ Olsf= WAL] elMelwo|gcl. BaalO= DIO-NASH OR OAL DA-17262 MlO}BEIO|= Chl NAFLD Activiy Score} 2) SE HAM BHO! YOM FE MOIS Sache uso] wsetch So] 2) SAI BIS 8 AGS Be FAAS] Yel HS DA-1726 & OFPOIM USSISH, DA-1726 NSVRE MOHBFEIOISO! Ula MS 27} MEOlS EPID 248), UBSSOMM Cl SE AES Bact Oxyntomodulin?!? Oxyntomodulin(OXM)2 Glucagon(GCG) +8Al(GCGR) S GLP- 1Righicagon-lke peptide 1) +8H(GLP-1R) 01S ASAS Belstoi A FS UMD O42] DH/S S7MiA|o} wleolay AS ULE HEH. SclenceDirectl YEE! Eo Wet, PAYCS WHE OXME MZE Babe MEE Blt FAS WME + Uoo, elsel Maso] Dat Aol] Cle} MF LIVRSY AlSZI(NASH) Alo EMS Mow ef Beta act. 36AITO, > Heungkuk ops arises yas 3368 vaya DA-1726 2 91 Bab unertc T.. Se lige Doetucia | El gek SBE Stang Bn a ‘LB Rca Des Asocaton, FBS ARIEL 2242 DAMT726 OA O91 NOY Bat NAFLD Activity Score Hepatic Fibrosis ea Histological score ‘onto! SEMA — paras IB: Rvwican Dates Assocaton, B33 eH 2248 DAM1726 #2f 012.4 BE BE AEA eae DAT726 HO OGD 2BSF BE AAA DIONASH coral Semasluie 259 amaleg Bye Se DAct726 100 nmovhg A125, 200 nog ‘X20 Blu coler bron TREADA, BLAH, Sea EAE ARGO BORIS, BREA ITIVE, 7a. Heungkuk AITO, Dies nel: NASH 3368 EuAoPIA wena) ACE rename we ‘ma mel aE EE HL ‘mai melee ese ae S68 S01 623 OTS HEAT 0 MTS ARS ST BR IY 2 08 88k 88 Haute age 1903 ora 1252 Ba ‘eee wt 165 le 58st 1108 Tord 431210 B18 HY Woz) 45)? fois 101g 18198 aes ba Mo %S 8) mB UREA sg se GOB eae wa sie 2) ak B 20 18 TRE 1686178 01m) fa) 3 Bt 0S ae) ame SS 4109 035 aE HE asia, fa 54 aoa uy 83 aT 6.) mg23| 30 00 00 oN waa 1153 10049 mae 1085 size ce ec vais 735 59 "813100 wieor 27 20 SD HE a9 tig? tis as 57 Meee = 72d B_ HENNE 511545 teaS TS iB Nr) (sia) (96.2) ater t50 le yma eo ee ans aT ‘YOGA Mag ipwoimes 5431561 tee 201) at gears 1918 185230 SOS aS ASRS TT eeOMIETBM Tao) aS 22 2 2 B22 career 57 (158) (8) 3k mme5 mea mes asm 01ertai na (120) a) TRS a1 OI oe7 wa maT ita aT e018) 5826 80 8S 8H wo wa 03) 8) SI's) ee ec ec on on on on on 2018 (8) a) 2048 rR ees Gia Seek ors ates NonAT ma i2 wt 4S Fa eae Mel m2 T6289 De 199198 23 Da? Ran S003 22 SS res HB eanenn va 5247787 Pow 28 1) Bak cae et 150100180 4308s 83 ook (wa zr oso. 4316 tao ASSAKIE eons) igegE eae) ww 0 ai aa EE BN ‘a0 ai mae aE UE Pu ta Da eaea mo 4 (foe) 0 «02 a2m9 41.0 gana Salad 62620 i200 m0 B30 765867 THIN87 SU5s00 oTseEE Tham2 Ee ws tee 23 oat 1.9009 ammo 1.0000 10mn0 1.0000 SERRE en 63 en a en laisse) tos i 34 (63) a) m1 m5 202 no ANANSI) e443 (ios) 28H) 08 tt mgMPss aM ue m2 140 ea eo es) Ga) ea seas tA vee laa Ga 90 000g Pon 79 la wrest 63 an aa a Ps 13 to oa wes 9 BL 50) (30) FREE sapumewe (aa (192) (109) (ao, eas ma mp 2s? ns er Netty e117 TO Ae (3 20180 ete BTOA 3 322 os eg aa? NEEL 3 89 Ba ed Be) aug ag 13 wo ime a7 MSA. a Seka oma m7 035077, 120 MB ss) 19 (ro) ere at oie at op 30 22 uo 4 (900) S70 wR tee (82 aT 7 Fang) es i282 0 6.1 1800080 easpaMth HS 318 we me fa (32 (Woo) sa) Tee (033) 8 en wo ata) HS 18 «kw S 3817 4B BB om) is) ear 25 mB ora) (8) ims) enor MRSS ED 38Heungkuk 3368 ‘SOLON - 7b SGA, BAI ee AITO, 718 NIPIE4: NASH ALB 221 GAL SASH SBA 7 cae wae ALDARA ‘500000 seer em FRO ABA) alalgpq Fal8e9 oe [aul ed Besa wm a meets By waa sam ‘sme BOLE! - F7t BAL SEF HB Ba 2M BAL SAO GE RRR WY ges a Bam ARIAT szo000 sae ‘am ROI B7Z) aeige9 eee ‘on Priel a ae sue = eae By stow sn san ‘ng Bawa ND Aa HERA 391. Heungkuk IQ} /4}012. daca 71d nie: NASH SNO}CHS 128 718) Ba: 15% ort COVERWERST (o/ERIG) H HAR! HENEANGHOL AFB 8% OY Aol ie! | Holi 15% ~15% NEUTRAL (Shh HF 127482! SLEAIEALSHO| ASOD Ball SUE 58) A Seis) 15% ost UNDERWEIGHT (CHES BEE THe! BHERIeHO| ARHTONB Cel 5 la He ky ea 1d SAAR] EXE YI (07244 O98 319 718) Buy (94.1%) | Hold 5.9%) | Sel 0%) Compliance Notice = GARE Sa BAY OM A> BSE 1% Oly BASED ol gow, TMB 71RRNPH EE Mana ARE MBE AHO] BEC = $Me] zajea SA) g MEH S BAINE 4D] Bal GeAR wReiD A SALE! = Ble Soa] NBA Igoe als wise: 4] Sel HEAL wel FS AU! aol Lette - SE Niuo) INE UBEE Sole) Sg ANAPT wale HOM, Heungkuk Securities O| mort: Baas Bec.a => Heungkuk Securities O| mort: Baas Bec.so kuk Profile OU are HES ee HEE canane WS ee BAP ara BAM eee Beat vs tie SH ougacw z a B 8 8 a S$ a 8 g 2 g exaey 49]U89 sajes |eUO!NIISU|ooo Bae BSB 7 Heungkuk a Ba5a http://www heungkuksec.co.kr 2h) MBA] SEER AMBRE 22 32, 14891 Monee 148) BQH GH 02) 6742-3635 Bae GE 02) 739-6286